ESC 2025 Resource Hub  – 

Welcome to our resource hub for ESC 2025! This is a one-stop-shop for all your ESC needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

  1. Day-by-Day Conference Preview

Day-of Conference Reports

  1. ESC 2025 Day #1 Highlights
  2. ESC 2025 Day #2 Highlights
  3. ESC 2025 Day #3 Highlights
  4. ESC 2025 Day #4 Highlights

Diabetes Therapy Highlights

  1. Inaugural session welcomes attendees to the 75th ESC Congress with a theme on global health
  2. Post-hoc analysis of the SOUL trial shows benefit of Rybelsus (oral semaglutide) in heart failure outcomes
  3. Post-hoc analysis of the SELECT trial: Dr. Plutzky finds semaglutide reduces MACE, atrial fibrillation, and HF risk
  4. Post-hoc analysis of CREDENCE trial shows benefit of continued canagliflozin use in people with T2D, CKD, and eGFR <20 mL/min/1.73 m2
  5. Drs. Andreea Ciudin and Barbara McGowan push for new diagnostic framework of obesity and review treatment landscape
  6. Liraglutide is associated with improved outcomes for patients with HFpEF and obesity
  7. Combination therapy with SGLT-2 inhibitors and GLP-1 RAs reduce all-cause mortality in patients with T2D
  8. Multinational Emp-Activity study shows that empagliflozin improves quality of life and cardiac function in real-world patients with heart failure
  9. Impact of GLP-1 RAs on muscle loss: Lively debate discussing this effect is in cardiometabolic disease management
  10. Findings from FINEARTS-HF: Finerenone demonstrates efficacy for severe heart failure
  11. Post-hoc analysis of SURMOUNT-1: Over a quarter of tirzepatide group meets clinical cardiometabolic targets
  12. Post-hoc analysis of the SOUL trial shows benefits of Rybelsus (oral semaglutide) for improving cardiovascular markers
  13. Pooled analysis of the SCORED and SOLOIST-WHF trials show consistent CV benefits of sotagliflozin in older adults
  14. Prof. Naveed Sattar calls for the targeting of prediabetes to reduce cardiovascular risk
  15. Do triglycerides matter? Decoding a key risk factor for ASCVD
  16. Cardiovascular outcomes in a SELECT-like obesity population: Real-world insights from the Swedish AROS study
  17. Save lives, hearts, and kidneys: Dr. Katherine Tuttle provides an overview of CKD management in diabetes
  18. Evidence-based strategies to address the “conundrum” of HFpEF: SGLT-2 inhibitors, MRAs, inflammation targets, and incretin therapies
  19. Factors associated with difficult-to-manage hypertension in T2D
  20. Increasing trends of cardiovascular mortality rates related to hypertension and diabetes in the US
  21. Dapagliflozin is safe for use in patients hospitalized for acute heart failure
  22. Real-world STEER study finds semaglutide is superior to tirzepatide for CV risk reduction
  23. Post-hoc analysis of the SURMOUNT-5 trial: Tirzepatide may have superior projected 10-year CV risk reduction compared to semaglutide
  24. Post-hoc analysis of the CONFIDENCE trial: Simultaneous initiation of finerenone and empagliflozin rapidly reduces albuminuria across KDIGO risk categories
  25. Population-based study spanning two decades shows associations of serum insulin levels with cardiovascular disease incidence and mortality
  26. Comparing glucose-lowering agents for atherosclerotic plaque prevention using coronary CT angiography
  27. Post-hoc analysis of the STRIDE trial finds consistent benefits of semaglutide on PAD regardless of sex
  28. Diabetes and prediabetes as risk factors for heart failure: Population-based cohort study highlight potential for preventative efforts
  29. Targeting A1c goals for renal function in patients with chronic coronary syndrome
  30. SGLT-2 inhibitors demonstrate heterogeneous effects in people with diabetes and without established cardiovascular disease
  31. Damaged hearts require more sleep: Mechanistic answers to why sleep improves cardiovascular health
  32. KOL Commentary on cardiovascular benefits of semaglutide and tirzepatide
  33. GLP-1 RAs and SGLT-2 inhibitors are underutilized in primary care for patients with diabetes and CAD
  34. Glucose lowering therapies should be prescribed before and after MI among patients with T2D
  35. A large-scale study quantifies the impact of age of onset and duration of T2D on life expectancy and serious health outcomes
  36. Systematic review and meta-analysis reinforce the efficacy and safety of GLP-1 RAs in obesity-related HFpEF
  37. Cardiovascular-kidney-metabolic syndrome is prevalent in healthy populations and linked to mortality
  38. Transitioning from overweight childhood status to normal BMI in adulthood mitigates cardiovascular-kidney-metabolic risks
  39. Prediabetes increases cardiovascular disease risk by a (very) statistically significant 21%, a major change upwards
  40. His Majesty King Felipe VI encourages continued focus on addressing cardiovascular disease, promoting prevention and raising awareness
  41. Cardiology beyond borders: What this means in practice
  42. Broad global health challenges continue

Previous ESC Coverage on CCKB

  1. ESC 2024 Resource Hub
  2. ESC 2023 Resource Hub
  3. ESC 2022 Resource Hub
  4. ESC 2021 Resource Hub
  5. ESC 2020 Full Report
  6. ESC 2019 Full Report
  7. ESC 2018 Full Report
  8. ESC 2017 Full Report
ESC 2025 Resource Hub -
Top